Form 4: Processa Pharmaceuticals Director Receives Significant Restricted Stock Grant

Processa Pharmaceuticals, Inc. Director Justin W. Yorke was granted 175,299 shares of restricted stock, with a portion contingent on stockholder approval and vesting by mid-2026.

Summary

• Director Justin W. Yorke of Processa Pharmaceuticals, Inc. (PCSA) was granted 175,299 shares of restricted stock on July 24, 2025.
• The grant was made under the company's 2019 Omnibus Incentive Plan.
• 125,999 of these shares are subject to stockholder approval of the revised Omnibus Plan.
• The restricted stock vests on the earlier of June 30, 2026, or the next annual meeting of stockholders, subject to certain distribution requirements.
• Following this transaction, Mr. Yorke beneficially owns 206,505 shares of common stock.

Sentiment

Score: 6

Explanation: The grant of restricted stock to a director is generally a neutral to slightly positive event, as it aligns interests. However, the contingency on stockholder approval for a significant portion introduces a minor element of uncertainty, preventing a higher score.

Positives

• Granting of restricted stock to a director aligns management's interests with those of shareholders.
• The shares are granted under an existing incentive plan, indicating a structured approach to executive compensation.

Negatives

• A portion of the grant (125,999 shares) is contingent on future stockholder approval, introducing a degree of uncertainty.
• Restricted stock grants can lead to dilution for existing shareholders upon vesting.

Risks

• The grant of 125,999 restricted shares is contingent on stockholder approval of the revised 2019 Omnibus Incentive Plan, meaning these shares may not be fully realized if approval is not obtained.
• Vesting is subject to "certain distribution requirements" which are not detailed, potentially introducing conditions that could affect the final realization of the shares.

Future Outlook

The restricted stock is set to vest on the earlier of June 30, 2026, or the next annual meeting of stockholders, contingent on certain distribution requirements. A significant portion of the grant (125,999 shares) also awaits stockholder approval of the revised 2019 Omnibus Incentive Plan.

Industry Context

In the pharmaceutical and biotech industry, incentive plans and restricted stock grants are common tools to attract, retain, and motivate key personnel, including directors, by aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• Granting restricted stock to directors is a standard practice across many industries, including pharmaceuticals, to incentivize long-term commitment and align interests.
• The contingency on stockholder approval for a portion of the grant is also a common governance practice for revised incentive plans.

Corporate Governance

Related Party Transactions

• The grant of restricted stock to a director is considered a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting of shares; improved alignment of director's interests with shareholder value.
• Director (Justin W. Yorke): Receives equity compensation, aligning his financial interests with the company's long-term performance.

Next Steps

• Stockholder vote on the revised 2019 Omnibus Incentive Plan to approve 125,999 shares of the restricted stock grant.
• Vesting of the restricted stock on the earlier of June 30, 2026, or the next annual meeting of stockholders, subject to distribution requirements.

Key Dates

Keywords

Processa Pharmaceuticals, PCSA, Justin W. Yorke, Restricted Stock, Stock Grant, Director Compensation, SEC Form 4, Insider Transaction, Omnibus Incentive Plan, Stockholder Approval